Mata, J. R., Zahurak, M., Rosen, N., DeZern, A. E., Jones, R. J., & Ambinder, A. J. (2024). Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy, 30(6), 588–596. https://doi.org/10.1016/j.jtct.2024.03.018

Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., Shaffer, B. C., El Jurdi, N., Loren, A. W., Solh, M., Hall, A. C., Alousi, A. M., Jamy, O. H., Perales, M.-A., Yao, J. M., … Holtan, S. G. (2023). Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. New England Journal of Medicine, 388(25), 2338–2348. https://doi.org/10.1056/nejmoa2215943

Tan, A. R., Chan, N., Kiesel, B. F., Stein, M. N., Moss, R. A., Malhotra, J., Aisner, J., Shah, M., Gounder, M., Lin, H., Kane, M. P., Lin, Y., Ji, J., Chen, A., Beumer, J. H., & Mehnert, J. M. (2021). A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. Cancer Chemotherapy and Pharmacology, 89(1), 49–58. https://doi.org/10.1007/s00280-021-04350-x